Inspire Medical Systems, Inc. (INSP)
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Inspire Medical's Inspire V rollout, broader approvals and clinical evidence support growth despite coding and reimbursement pressures.
Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript
Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript
INSP Highlights New OSA Data and PREDICTOR Study at SLEEP 2026
Inspire Medical's SLEEP 2026 updates spotlight new Inspire V data, remote patient tools and research supporting wider OSA therapy adoption.
Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff
Inspire Medical Systems faces a sharp revenue slowdown due to temporary CPT coding and CMS Project WISeR disruptions, not fundamental business weakness. INSP maintains a robust balance sheet with ~$400M in liquidity and zero debt, providing downside insulation and supporting a 1x EV/sales valuation at depressed prices. Competitive threats from Nyxoah and GLP-1 therapies are manageable, with IP litigation successes and GLP-1s potentially expanding INSP's addressable market.
Why Is Inspire (INSP) Down 15.9% Since Last Earnings Report?
Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
Inspire Medical Systems, Inc. (INSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Inspire Medical Systems, Inc. (INSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Inspire: Why I'm Still Rating The Stock A 'Sell' After The Earnings Dip
Inspire Medical Systems, Inc. remains under pressure as Q1 revenue grew just 1.6% and management slashed 2026 guidance by up to 10%. INSP faces intensifying competition from GLP-1s and rival devices, reimbursement headwinds, and coding challenges with its new Inspire 5 system. Territory contraction and a shift to supporting existing accounts signal operational headwinds and a retreat from high-growth expansion.
Inspire Medical Q1 Earnings Beat Estimates, 2026 View Cut, Stock Down
INSP beats Q1 estimates but slashes 2026 outlook as reimbursement disruptions and WISeR program weigh on growth and procedure volumes.
Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript
Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript
Inspire (INSP) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inspire Medical Systems (INSP) Q1 Earnings and Revenues Top Estimates
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to earnings of $0.1 per share a year ago.
Analysts Estimate Inspire Medical Systems (INSP) to Report a Decline in Earnings: What to Look Out for
Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
